Literature DB >> 16445974

Real-time reverse transcription PCR and the detection of occult disease in colorectal cancer.

Stephen A Bustin1, Reinhold Mueller.   

Abstract

Molecular diagnostics offers the promise of accurately matching patient with treatment, and a resultant significant effect on improved disease outcome. More specifically, the real-time reverse transcription polymerase chain reaction (qRT-PCR), with its combination of conceptual simplicity and technical utility, has the potential to become a valuable analytical tool for the detection of mRNA targets from tissue biopsies and body fluids. Its potential is particularly promising in cancer patients, both as a prognostic assay and for monitoring response to therapy. Colorectal cancer provides an instructive paradigm for this potential as well as the problems associated with its use as a clinical assay. Currently, histopathological staging, which provides a static description of the anatomical extent of tumour spread within a surgical specimen, defines patient prognosis. The detection of lymph node (LN) metastasis constitutes the most important prognostic factor in colorectal cancer and as the primary indicator of systemic disease spread, LN status determines the choice of postoperative adjuvant chemotherapy. However, its limitations are emphasised by the considerable prognostic heterogeneity of patients within a given tumour stage: not all patients with LN-negative cancers are cured and not all patients with LN-positive tumours die from their disease. This has resulted in a search for more accurate staging protocols and has seen the introduction of the concept of "molecular staging", the incorporation of molecular parameters into clinical tumour staging. Quantification of disease-associated mRNA is one such parameter that utilises the qRT-PCR assay's potential for generating quantitative results. These are not only more informative than qualitative data, but contribute to assay standardisation and quality management. This review provides an assessment of the practical value to the clinician of RT-PCR-based molecular diagnostics. It points out reasons for the many contradictory results encountered in the literature and concludes that there is an urgent need for standardisation at every level, starting with pre-assay sample acquisition and template preparation, assay protocols and post-assay analysis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16445974     DOI: 10.1016/j.mam.2005.12.002

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  8 in total

1.  Quantitative analysis of TEM-8 and CEA tumor markers indicating free tumor cells in the peripheral blood of colorectal cancer patients.

Authors:  Reza Raeisossadati; Moein Farshchian; Azita Ganji; Alieza Tavassoli; Arash Velayati; Ezzat Dadkhah; Somaye Chavoshi; Mostafa Mehrabi Bahar; Bahram Memar; Mohammad Taghi Rajabi Mashhadi; Hossein Naseh; Mohammad Mahdi Forghanifard; Meysam Moghbeli; Omeed Moaven; Mohammad Reza Abbaszadegan
Journal:  Int J Colorectal Dis       Date:  2011-05-15       Impact factor: 2.571

2.  Evaluation of suitable reference genes for normalization of real-time reverse transcription PCR analysis in colon cancer.

Authors:  Lise Aa Sørby; Solveig N Andersen; Ida R K Bukholm; Morten B Jacobsen
Journal:  J Exp Clin Cancer Res       Date:  2010-11-08

3.  Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis.

Authors:  Piergiorgio Modena; Francesca R Buttarelli; Rosalba Miceli; Elena Piccinin; Caterina Baldi; Manila Antonelli; Isabella Morra; Libero Lauriola; Concezio Di Rocco; Maria Luisa Garrè; Iacopo Sardi; Lorenzo Genitori; Roberta Maestro; Lorenza Gandola; Federica Facchinetti; Paola Collini; Gabriella Sozzi; Felice Giangaspero; Maura Massimino
Journal:  Neuro Oncol       Date:  2012-10-17       Impact factor: 12.300

4.  Evaluation of the adenocarcinoma-associated gene AGR2 and the intestinal stem cell marker LGR5 as biomarkers in colorectal cancer.

Authors:  Manuel Valladares-Ayerbes; Moisés Blanco-Calvo; Margarita Reboredo; María J Lorenzo-Patiño; Pilar Iglesias-Díaz; Mar Haz; Silvia Díaz-Prado; Vanessa Medina; Isabel Santamarina; Sonia Pértega; Angélica Figueroa; Luis M Antón-Aparicio
Journal:  Int J Mol Sci       Date:  2012-04-05       Impact factor: 6.208

Review 5.  [Linear B-cell epitope prediction].

Authors:  Ia I Davydov; A G Tonevitskiĭ
Journal:  Mol Biol (Mosk)       Date:  2009 Jan-Feb

6.  Microarray-based identification and RT-PCR test screening for epithelial-specific mRNAs in peripheral blood of patients with colon cancer.

Authors:  Rossella Solmi; Giampaolo Ugolini; Giancarlo Rosati; Simone Zanotti; Mattia Lauriola; Isacco Montroni; Marco del Governatore; Antonello Caira; Mario Taffurelli; Donatella Santini; Domenico Coppola; Lia Guidotti; Paolo Carinci; Pierluigi Strippoli
Journal:  BMC Cancer       Date:  2006-10-20       Impact factor: 4.430

7.  Evaluation of alpha 1-antitrypsin and the levels of mRNA expression of matrix metalloproteinase 7, urokinase type plasminogen activator receptor and COX-2 for the diagnosis of colorectal cancer.

Authors:  Luis Bujanda; Cristina Sarasqueta; Angel Cosme; Elizabeth Hijona; José M Enríquez-Navascués; Carlos Placer; Eloisa Villarreal; Marta Herreros-Villanueva; María D Giraldez; Meritxell Gironella; Francesc Balaguer; Antoni Castells
Journal:  PLoS One       Date:  2013-01-02       Impact factor: 3.240

8.  Systematic large-scale meta-analysis identifies a panel of two mRNAs as blood biomarkers for colorectal cancer detection.

Authors:  Maria Teresa Rodia; Giampaolo Ugolini; Gabriella Mattei; Isacco Montroni; Davide Zattoni; Federico Ghignone; Giacomo Veronese; Giorgia Marisi; Mattia Lauriola; Pierluigi Strippoli; Rossella Solmi
Journal:  Oncotarget       Date:  2016-05-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.